Mipasetamab Uzoptirine

ADCT-601 · ADC Therapeutics S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Mipasetamab Uzoptirine, covering 2025-05-22 to 2025-05-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors [Phase 1]